Anthony Letai, Director of the National Cancer Institute, shared on X:
“Well-designed clinical trials help discoveries reach patients. Sustained investment in targeted therapies-including those affecting the RAS pathway-can improve the lives of adults with NF1 and help guide the next generation of treatments.
Other articles about NIH on OncoDaily.